Propranolol treatment for hemangioma of infancy: risks and recommendations.
Hemangioma of infancy is a condition that may be associated with significant morbidity. While evidence most supports the use of corticosteroids, there is no well-defined or Federal Drug Administration (FDA)-approved systemic therapy for hemangioma of infancy. All currently used treatments have significant risks. Dramatic improvement of complicated hemangioma of infancy to propranolol was recently reported, but details for initiating therapy, monitoring, and potential risks were not included. We present two infants treated with propranolol, who suffered complications and propose a treatment protocol to minimize potential adverse events.
Lawley
Leslie P
LP
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia 30322, USA. lpotter@emory.edu
Siegfried
Elaine
E
Todd
Jane L
JL
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006391:Hemangioma / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007223:Infant; D017410:Practice Guidelines as Topic; D011433:Propranolol / Q000008:administration & dosage* / Q000009:adverse effects*; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D011433:Propranolol